A data-driven atlas of CAR-based immunotherapy in lung cancer: Insights from multidatabase integration

地图集(解剖学) 免疫疗法 医学 肺 计算生物学 癌症研究 肺病 病理 免疫学 梅德林
作者
Fangkai He,Xingyu Zhu,Xiaolei Wang,Xinyu Ju,Fengmei Wu,Wenjuan Di,Shicheng Su,Hui Huang
出处
期刊:Pharmacological Research [Elsevier BV]
卷期号:231: 108368-108368
标识
DOI:10.1016/j.phrs.2026.108368
摘要

Lung cancer remains a leading cause of cancer-related mortality worldwide, and the clinical translation of chimeric antigen receptor (CAR)-based immunotherapy into solid tumors continues to be constrained by antigen heterogeneity, an immunosuppressive microenvironment, and stromal barriers that impede immune cell trafficking and curtail efficacy. Here, we present a comprehensive bibliometric analysis of CAR-based immunotherapy for lung cancer, drawing on publications indexed in the Web of Science Core Collection and Scopus between 2016 and 2025. Bibliometric and network analyses elucidate global research trajectories, collaboration patterns, and emergent therapeutic themes, while clinical trial data from ClinicalTrials.gov further appraise translational progress. This landscape has expanded rapidly, with growing emphasis on CAR engineering, microenvironment modulation, precision targeting, and combinatorial strategies. Clinical evidence, though drawn from a still-limited number of trials, indicates generally tolerable toxicity in most reported cases; nevertheless, severe and occasionally fatal adverse events have been documented, underscoring the need for continued vigilance in safety evaluation. Antitumor efficacy remains modest, reflecting persistent challenges in target selection, tumor accessibility, cellular persistence, and functional maintenance. Emerging strategies, including multi-target CAR architectures, rational drug combinations, and biomarker-guided patient stratification, may offer avenues for overcoming these limitations. This study furnishes a data-driven pharmacological atlas of CAR-based immunotherapy in lung cancer, illuminating key therapeutic targets, evolving treatment paradigms, and prospective opportunities for clinical translation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小马甲的应助被科研通管家采纳,获得10
刚刚
研友_VZG7GZ的应助被科研通管家采纳,获得10
刚刚
ding的应助被明亮的迎松采纳,获得10
刚刚
null的应助被科研通管家采纳,获得10
刚刚
JamesPei的应助被科研通管家采纳,获得10
1秒前
爆米花的应助被科研通管家采纳,获得10
1秒前
FashionBoy的应助被科研通管家采纳,获得10
1秒前
xing_xing的应助被科研通管家采纳,获得20
1秒前
Ava的应助被科研通管家采纳,获得10
1秒前
初景的应助被科研通管家采纳,获得20
1秒前
望石榴完成签到 ,获得积分10
1秒前
Jasper的应助被科研通管家采纳,获得10
1秒前
bkagyin的应助被科研通管家采纳,获得20
2秒前
2秒前
2秒前
搜集达人的应助被科研通管家采纳,获得10
2秒前
Akim的应助被科研通管家采纳,获得10
2秒前
无花果的应助被科研通管家采纳,获得30
2秒前
xing_xing的应助被科研通管家采纳,获得20
2秒前
lkk发布了新的文献求助10
2秒前
小蘑菇的应助被科研通管家采纳,获得10
2秒前
上官若男的应助被科研通管家采纳,获得10
3秒前
bkagyin的应助被科研通管家采纳,获得10
3秒前
慕青的应助被科研通管家采纳,获得10
3秒前
3秒前
3秒前
3秒前
英俊的铭的应助被科研通管家采纳,获得10
3秒前
田様的应助被科研通管家采纳,获得10
3秒前
3秒前
DW的应助被科研通管家采纳,获得20
4秒前
kkk发布了新的文献求助10
4秒前
情怀的应助被科研通管家采纳,获得10
4秒前
无情愫的应助被科研通管家采纳,获得10
4秒前
bkagyin的应助被科研通管家采纳,获得10
4秒前
大个的应助被科研通管家采纳,获得30
4秒前
脑洞疼的应助被科研通管家采纳,获得10
4秒前
wanci的应助被科研通管家采纳,获得10
4秒前
天天快乐的应助被科研通管家采纳,获得10
5秒前
852的应助被sy采纳,获得10
5秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184240
求助须知:如何正确求助?哪些是违规求助? 9573297
关于积分的说明 21830585
捐赠科研通 7781300
什么是DOI,文献DOI怎么找? 3434285
关于科研通互助平台的介绍 2558389
邀请新用户注册赠送积分活动 2480814